Cancer patients undergoing chemotherapy.Immunosuppressed patients are at high risk for developing invasive fungal disease, which is often difficult to diagnose. You can also find information concerning the applications and latest findings of (1→3)-β-D-glucan testing in patients on the website, as well as links to other websites of interest to the mycotic disease community. We currently hold certifications and licenses in Massachusetts, California, Maryland, Pennsylvania and Rhode Island. The laboratory is directed by Patricia Devine, M.D., and along with the expert staff at Beacon Diagnostics ® Laboratory, we provide clients with rapid diagnostic and analytical services, to assist in the medical evaluation of patients suspected of having invasive fungal infections.

Serving clinical and reference laboratories, we offer a rapid, cost-effective alternative to in-house testing. 22D1021258) reference laboratory specializing in (1→3)-β-D-glucan analysis services to support the diagnosis of Invasive Fungal Disease (IFD). Beacon is a fully CLIA-certified (license no.

Download diag laboratories